Recombinant anti-human-amyloïde Beta-antilichaam (Lecanemab Biosimilar)

Target: Amyloid Beta Generic name: Lecanemab Product Origin: Recombinant in Human cells People with Alzheimerâ€TMs disease have a protein called amyloid that continuously builds up in the brain. It starts with small forms of amyloid protein. These may clump together into larger forms, which can damage the brain cells. As they continue to build up, they can form harmful amyloid brain plaques. Lecanemab is humanized monoclonal antibodies targeting cerebral amyloid-beta (A-2) plaques. References: 1. Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid--2-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15 (2) :73-88..

Amyloid beta, Lecanemab

Amyloid

620

P05067

Human

Functional Assay, ELISA, ICC/IF, FACS

Purified from cell culture supernatant by affinity chromatography

Purified

Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization.Sterile

Store at -20°C. Avoid repeated freeze and thaw cycles.

Specificity: Human Amyloid beta. Inquire for more than 1 mg quantities.

Human IgG1